Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 55341306700

Activities

Collapse all

Works (38)

De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?

Journal of Clinical Oncology
2025-03-20 | Journal article
DOI: 10.1200/JCO-24-02347
Contributors: Jordi Remon; Martina Bortolot; Paolo Bironzo; Francesco Cortiula; Jessica Menis; Mariana Brandao; Jarushka Naidoo; Robin van Geel; Noemi Reguart; Oscar Arrieta et al.
Source: check_circle
Crossref

The gut microbiota during tamoxifen therapy in patients with breast cancer

Scientific Reports
2025-03-06 | Journal article
DOI: 10.1038/s41598-025-91734-1
Contributors: Lars E. Hillege; David J. M. Barnett; Janine Ziemons; Romy Aarnoutse; Judith de Vos-Geelen; Robin van Geel; Maaike de Boer; Yvonne E. A. van Riet; Jeroen Vincent; John Penders et al.
Source: check_circle
Crossref

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer

International Journal of Cancer
2024 | Journal article
DOI: 10.1002/ijc.34742
EID:

2-s2.0-85174316593

Part of ISSN: 10970215 00207136
Contributors: van Veelen, A.; Veerman, G.D.M.; Verschueren, M.V.; Gulikers, J.L.; Steendam, C.M.J.; Brouns, A.J.W.M.; Dursun, S.; Paats, M.S.; Tjan-Heijnen, V.C.G.; van der Leest, C. et al.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Intra-Individual Variability of Direct Oral Anticoagulant Levels in Frail Older Patients upon, during, and after Acute Hospitalization: the DOAC-FRAIL Study

Journal of the American Medical Directors Association
2024 | Journal article
DOI: 10.1016/j.jamda.2024.105280
EID:

2-s2.0-85205664786

Part of ISSN: 15389375 15258610
Contributors: de Jong, M.J.; Saadan, H.; van der Hooft, B.H.M.; Hellenbrand, D.L.S.; Brüggemann, R.A.G.; Ten Cate, H.; van Kuijk, S.M.J.; van Geel, R.M.J.M.; Henskens, Y.M.C.; Winckers, K. et al.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

JTO Clinical and Research Reports
2024 | Journal article
DOI: 10.1016/j.jtocrr.2024.100656
EID:

2-s2.0-85188429413

Part of ISSN: 26663643
Contributors: Gulikers, J.L.; Veerman, G.D.M.; Jebbink, M.; Kruithof, P.D.; Steendam, C.M.J.; Boosman, R.J.; Mathijssen, R.H.J.; Tjan-Heijnen, V.C.G.; Driessen, J.H.M.; Dursun, S. et al.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon

Research Square
2024 | Other
DOI: 10.21203/rs.3.rs-3911071/v1
EID:

2-s2.0-85193084679
Contributors: Ziemons, J.; Hillege, L.E.; Aarnoutse, R.; de Vos-Geelen, J.; Valkenburg-Van Iersel, L.; Mastenbroek, J.; van Geel, R.; Barnett, D.J.M.; Rensen, S.S.; van Helvoort, A. et al.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

British Journal of Cancer
2024 | Journal article
DOI: 10.1038/s41416-024-02744-1
EID:

2-s2.0-85195688272

Part of ISSN: 15321827 00070920
Contributors: Gulikers, J.L.; Otten, L.-S.; Hendriks, L.E.L.; Winckers, K.; Henskens, Y.; Leentjens, J.; van den Heuvel, M.M.; ter Heine, R.; Croes, S.; Piet, B. et al.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer

European Journal of Drug Metabolism and Pharmacokinetics
2024 | Journal article
DOI: 10.1007/s13318-024-00904-5
EID:

2-s2.0-85196022013

Part of ISSN: 21070180 03787966
Contributors: Westra, N.; Kruithof, P.D.; Croes, S.; van Geel, R.M.J.M.; Hendriks, L.E.L.; Touw, D.J.; Oude Munnink, T.H.; Mian, P.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon

BMC Microbiology
2024-06-26 | Journal article
DOI: 10.1186/s12866-024-03384-4
Contributors: Janine Ziemons; Lars E. Hillege; Romy Aarnoutse; Judith de Vos-Geelen; Liselot Valkenburg-van Iersel; Jasper Mastenbroek; Robin van Geel; David J. M. Barnett; Sander S. Rensen; Ardy van Helvoort et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink Aurum and GOLD

Pharmacoepidemiology and Drug Safety
2023 | Journal article
DOI: 10.1002/pds.5637
EID:

2-s2.0-85159921506

Part of ISSN: 10991557 10538569
Contributors: Gulikers, J.L.; van Veelen, A.J.; Driessen, J.H.M.; Souverein, P.C.; Tjan-Heijnen, V.C.G.; Hendriks, L.E.L.; van Geel, R.M.J.M.; Croes, S.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Pharmacokinetic boosting of osimertinib: The OSIBOOST trial. Perspective for cost reduction: Boosting anticancer drugs,PERSPECTIEF VOOR KOSTENREDUCTIE: BOOSTEN VAN ANTIKANKERMIDDELEN

Pharmaceutisch Weekblad
2023 | Journal article
EID:

2-s2.0-85179609707

Part of ISSN: 00316911
Contributors: van Veelen, A.; Hendriks, L.; van Geel, R.; Croes, S.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
2023 | Journal article
DOI: 10.1016/j.jchromb.2023.123918
EID:

2-s2.0-85177990206

Part of ISSN: 1873376X 15700232
Contributors: Kruithof, P.D.; de Beer, Y.M.; Gulikers, J.L.; Stolk, L.M.L.; Hendriks, L.E.L.; Croes, S.; van Geel, R.M.J.M.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

Development and validation of an HPLC–MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2‐EDTA plasma

Biomedical Chromatography
2023-06 | Journal article
DOI: 10.1002/bmc.5628
Part of ISSN: 0269-3879
Part of ISSN: 1099-0801
Contributors: Judith Gulikers; Ard J. van Veelen; Elishia M. J. Sinkiewicz; Yvo M. de Beer; Mariëlle Slikkerveer; Leo M. L. Stolk; Vivianne C. G. Tjan‐Heijnen; Lizza E. L. Hendriks; Sander Croes; Robin M. J. M. van Geel
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Targeted Oncology
2023-05 | Journal article
DOI: 10.1007/s11523-023-00958-6
Part of ISSN: 1776-2596
Part of ISSN: 1776-260X
Contributors: Rob ter Heine; Michel M. van den Heuvel; Berber Piet; Maarten J. Deenen; Anthonie J. van der Wekken; Lizza E. L. Hendriks; Sander Croes; Robin M. J. M. van Geel; Frank G. A. Jansman; Rogier C. Boshuizen et al.
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC

Current Problems in Cancer: Case Reports
2022 | Journal article
DOI: 10.1016/j.cpccr.2022.100186
EID:

2-s2.0-85138508667

Part of ISSN: 26666219
Contributors: Gulikers, J.L.; Slikkerveer, M.; Winckers, K.; Hendriks, L.E.L.; Dursun, S.; Croes, S.; van Geel, R.M.J.M.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier
grade
Preferred source (of 2)‎

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial

Lung Cancer
2022-09 | Journal article
DOI: 10.1016/j.lungcan.2022.07.012
Part of ISSN: 0169-5002
Contributors: Ard van Veelen; Judith Gulikers; Lizza E.L. Hendriks; Safiye Dursun; Juanita Ippel; Egbert F. Smit; Anne-Marie C. Dingemans; Robin van Geel; Sander Croes
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Cannabinoid consumption among cancer patients receiving systemic anti-cancer treatment in the Netherlands

Journal of Cancer Research and Clinical Oncology
2022-07-02 | Journal article
DOI: 10.1007/s00432-022-04085-z
Part of ISSN: 0171-5216
Part of ISSN: 1432-1335
Contributors: Robin van geel
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

Cancer Epidemiology
2022-06 | Journal article
DOI: 10.1016/j.canep.2022.102149
Part of ISSN: 1877-7821
Contributors: Ard van Veelen; Shahab Abtahi; Patrick Souverein; Johanna H.M. Driessen; Olaf H. Klungel; Anne-Marie C. Dingemans; Robin van Geel; Frank de Vries; Sander Croes
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer

European Respiratory Review
2022-06-30 | Journal article
DOI: 10.1183/16000617.0004-2022
Part of ISSN: 0905-9180
Part of ISSN: 1600-0617
Contributors: Robin van geel
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Comment on “Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case–control study from Denmark”

Journal of the American Academy of Dermatology
2021-12 | Journal article
DOI: 10.1016/j.jaad.2019.01.087
Part of ISSN: 0190-9622
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run

Biomedical Chromatography
2021-12 | Journal article
DOI: 10.1002/bmc.5224
Part of ISSN: 0269-3879
Part of ISSN: 1099-0801
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Nivolumab exposure in a hemodialysis patient with metastatic melanoma

Melanoma Research
2021-12 | Journal article
DOI: 10.1097/cmr.0000000000000775
Part of ISSN: 0960-8931
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer

The Oncologist
2021-04-01 | Journal article
DOI: 10.1002/onco.13631
Part of ISSN: 1083-7159
Part of ISSN: 1549-490X
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Cancer Chemotherapy and Pharmacology
2020-05 | Journal article
DOI: 10.1007/s00280-020-04066-4
Part of ISSN: 0344-5704
Part of ISSN: 1432-0843
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Validation of an analytical method using HPLC–MS/MS to quantify osimertinib in human plasma and supplementary stability results

Biomedical Chromatography
2020-04 | Journal article
DOI: 10.1002/bmc.4771
Part of ISSN: 0269-3879
Part of ISSN: 1099-0801
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

British Journal of Cancer
2020-04-14 | Journal article
DOI: 10.1038/s41416-020-0776-z
Part of ISSN: 0007-0920
Part of ISSN: 1532-1827
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer

Future Oncology
2020-02 | Journal article
DOI: 10.2217/fon-2019-0748
Part of ISSN: 1479-6694
Part of ISSN: 1744-8301
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

The role of misclassification of exposure in the association between aspirin and nonsteroidal anti‐inflammatory drug use and keratinocyte cancers

British Journal of Dermatology
2019-09 | Journal article
DOI: 10.1111/bjd.18134
Part of ISSN: 0007-0963
Part of ISSN: 1365-2133
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Rational combination therapy 'defeats' resistance mechanism: Perspective in colorectal carcinoma with BRAF mutation,Perspectief bij colorectaal carcinoom met BRAF-mutatie

Pharmaceutisch Weekblad
2017 | Journal article
EID:

2-s2.0-85031022546

Part of ISSN: 00316911
Contributors: Van Geel, R.M.J.M.; Beijnen, J.H.; Schellens, J.H.M.
Source: Self-asserted source
Robin van geel via Scopus - Elsevier

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Cancer Discovery
2017-06 | Journal article
DOI: 10.1158/2159-8290.cd-16-0795
Part of ISSN: 2159-8274
Part of ISSN: 2159-8290
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Journal of Clinical Oncology
2016-12-20 | Journal article
DOI: 10.1200/jco.2016.67.5991
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Journal of Clinical Oncology
2016-12-20 | Journal article
DOI: 10.1200/jco.2016.67.5942
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Pronounced between‐subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers

British Journal of Clinical Pharmacology
2016-09 | Journal article
DOI: 10.1111/bcp.13007
Part of ISSN: 0306-5251
Part of ISSN: 1365-2125
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Cancer Research
2016-08-01 | Journal article
DOI: 10.1158/0008-5472.can-16-0396
Part of ISSN: 0008-5472
Part of ISSN: 1538-7445
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Crizotinib-induced fatal fulminant liver failure

Lung Cancer
2016-03 | Journal article
DOI: 10.1016/j.lungcan.2015.12.010
Part of ISSN: 0169-5002
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Treatment Individualization in Colorectal Cancer

Current Colorectal Cancer Reports
2015-12 | Journal article
DOI: 10.1007/s11888-015-0288-z
Part of ISSN: 1556-3790
Part of ISSN: 1556-3804
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

Bioanalysis
2015-03 | Journal article
DOI: 10.4155/bio.14.304
Part of ISSN: 1757-6180
Part of ISSN: 1757-6199
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎

Concise Drug Review: Pazopanib and Axitinib

The Oncologist
2012-08-01 | Journal article
DOI: 10.1634/theoncologist.2012-0055
Part of ISSN: 1083-7159
Part of ISSN: 1549-490X
Source: Self-asserted source
Robin van geel
grade
Preferred source (of 2)‎
How many people are using ORCID?